

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:sssptaul25zxf

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

NEWS 1 Web Page URLs for STN Seminar Schedule - N. America
NEWS 2 "Ask CAS" for self-help around the clock
NEWS 3 SEP 01 New pricing for the Save Answers for SciFinder Wizard within
STN Express with Discover!
NEWS 4 OCT 28 KOREAPAT now available on STN
NEWS 5 NOV 30 PHAR reloaded with additional data
NEWS 6 DEC 01 LISA now available on STN
NEWS 7 DEC 09 12 databases to be removed from STN on December 31, 2004
NEWS 8 DEC 15 MEDLINE update schedule for December 2004
NEWS 9 DEC 17 ELCOM reloaded; updating to resume; current-awareness
alerts (SDIs) affected
NEWS 10 DEC 17 COMPUAB reloaded; updating to resume; current-awareness
alerts (SDIs) affected
NEWS 11 DEC 17 SOLIDSTATE reloaded; updating to resume; current-awareness
alerts (SDIs) affected
NEWS 12 DEC 17 CERAB reloaded; updating to resume; current-awareness
alerts (SDIs) affected
NEWS 13 DEC 17 THREE NEW FIELDS ADDED TO IFIPAT/IFIUDB/IFICDB
NEWS 14 DEC 30 EPFULL: New patent full text database to be available on STN
NEWS 15 DEC 30 CAPLUS - PATENT COVERAGE EXPANDED
NEWS 16 JAN 03 No connect-hour charges in EPFULL during January and
February 2005
NEWS 17 JAN 26 CA/CAPLUS - Expanded patent coverage to include the Russian
Agency for Patents and Trademarks (ROSPATENT)
NEWS 18 FEB 10 STN Patent Forums to be held in March 2005
NEWS 19 FEB 16 STN User Update to be held in conjunction with the 229th ACS
National Meeting on March 13, 2005

NEWS EXPRESS JANUARY 10 CURRENT WINDOWS VERSION IS V7.01a, CURRENT
MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP),
AND CURRENT DISCOVER FILE IS DATED 10 JANUARY 2005

NEWS HOURS STN Operating Hours Plus Help Desk Availability
NEWS INTER General Internet Information
NEWS LOGIN Welcome Banner and News Items
NEWS PHONE Direct Dial and Telecommunication Network Access to STN
NEWS WWW CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that
specific topic.

All use of STN is subject to the provisions of the STN Customer
agreement. Please note that this agreement limits use to scientific
research. Use for software development or design or implementation
of commercial gateways or other similar uses is prohibited and may
result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 17:10:13 ON 19 FEB 2005

=> file caplus,ca,medline,biosis,uspatfull,drugu,wpids

COST IN U.S. DOLLARS	SINCE FILE	TOTAL
FULL ESTIMATED COST	ENTRY	SESSION
	0.63	0.63

FILE 'CAPLUS' ENTERED AT 17:11:59 ON 19 FEB 2005
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
 COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'CA' ENTERED AT 17:11:59 ON 19 FEB 2005
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
 COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'MEDLINE' ENTERED AT 17:11:59 ON 19 FEB 2005

FILE 'BIOSIS' ENTERED AT 17:11:59 ON 19 FEB 2005
 Copyright (c) 2005 The Thomson Corporation.

FILE 'USPATFULL' ENTERED AT 17:11:59 ON 19 FEB 2005
 CA INDEXING COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'DRUGU' ENTERED AT 17:11:59 ON 19 FEB 2005
 COPYRIGHT (C) 2005 THE THOMSON CORPORATION

FILE 'WPIDS' ENTERED AT 17:11:59 ON 19 FEB 2005
 COPYRIGHT (C) 2005 THE THOMSON CORPORATION

=> s hydroxycitric (w) acid
 5 FILES SEARCHED...
 L1 726 HYDROXYCITRIC (W) ACID

 => s l1 and inflammation
 L2 38 L1 AND INFLAMMATION

 => dup remove l2
 PROCESSING COMPLETED FOR L2
 L3 33 DUP REMOVE L2 (5 DUPLICATES REMOVED)

 => d l3 1-33 bib, ab

L3 ANSWER 1 OF 33 CAPLUS COPYRIGHT 2005 ACS on STN DUPLICATE 1
 AN 2005:29191 CAPLUS
 DN 142:107394
 TI (-)-hydroxycitric acid for controlling
 inflammation
 IN Clouatre, Dallas L.
 PA Glykon Technologies Group, LLC, USA
 SO PCT Int. Appl., 13 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005002565	A1	20050113	WO 2004-US21541	20040702
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
	RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
	US 2005032901	A1	20050210	US 2003-612648	20030702

PRAI US 2003-612648 A 20030702
US 2002-393661P P 20020702

AB This invention relates to compns. containing (-)-**hydroxycitric acid** useful for reducing **inflammation** and regulating inflammatory responses and processes. Specifically, the invention provides a method of reducing **inflammation** useful for preventing, treating and ameliorating conditions involving **inflammation**, e.g., cardiovascular diseases, cancer, arthritis and a variety of other conditions that involve excessive **inflammation**

RE.CNT 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 2 OF 33 USPATFULL on STN

AN 2005:38221 USPATFULL

TI (-)-**Hydroxycitric acid** for controlling **inflammation**

IN Clouatre, Dallas L., Santa Monica, CA, UNITED STATES

PI US 2005032901 A1 20050210

AI US 2003-612648 A1 20030702 (10)

PRAI US 2002-393661P 20020702 (60)

DT Utility

FS APPLICATION

LREP Patent Administrator, Epstein Becker and Green PC, 111 Huntington Avenue, 26th Floor, Boston, MA, 02199

CLMN Number of Claims: 6

ECL Exemplary Claim: 1

DRWN No Drawings

LN.CNT 422

AB The invention teaches that supplementation with (-)-hydroxycitrate constitutes a novel means of reducing **inflammation** and is useful for preventing, treating and ameliorating conditions involving **inflammation**. The discovery that HCA has **inflammation** -moderating effects allows for the creation of novel and more efficacious approaches to preventing and ameliorating cardiovascular diseases, cancer, arthritis and a variety of other conditions that involve excessive **inflammation**. Inasmuch as one element common to advancing years is an increased level of generalized **inflammation**, the invention further lends itself to reducing or delaying this aspect of aging, one factor in what is known as sarcopenia. Furthermore, this discovery makes possible the development of adjuvant modalities which can be used to improve the results realized with other treatment compounds while at the same time reducing the side effects normally found with such drugs. HCA delivered in the form of its potassium salt is efficacious at a daily dosage (bid or tid) of between 750 mg and 10 grams, preferably at a dosage of between 3 and 6 grams for most individuals. A daily dosage above 10 grams might prove desirable under some circumstances, such as with extremely large or resistant individuals, but this level of intake is not deemed necessary under normal conditions.

L3 ANSWER 3 OF 33 USPATFULL on STN

AN 2005:11784 USPATFULL

TI Treating cachexia and excessive catabolism with (-)-**hydroxycitric acid**

IN Clouatre, Dallas L., Santa Monica, CA, UNITED STATES

PI US 2005009919 A1 20050113

AI US 2003-616321 A1 20030707 (10)

DT Utility

FS APPLICATION

LREP GREENBERG TRAURIG, LLP, ONE INTERNATIONAL PLACE, 20th FL, ATTN: PATENT ADMINISTRATOR, BOSTON, MA, 02110

CLMN Number of Claims: 6

ECL Exemplary Claim: 1

DRWN 4 Drawing Page(s)

LN.CNT 558

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The inventor has discovered that (-)-**hydroxycitric**

acid (including the forms of its various salts) is useful for treating and ameliorating cachexia, health-threatening catabolism and unhealthful weight loss, such as is characteristic of sarcopenia. The dosage will depend on factors such as the starting weight of the individual and the percentage of the calories in the diet derived from fats. On a 30 percent fat diet, an efficacious daily dosage for most individuals will be between 250 mg and 3 grams per day. It may prove beneficial to deliver the desired dosage only once per day, preferably prior to the noon meal. The weight-gain effects of HCA are compromised by the actions compounds such as caffeine and ephedrine, hence these should be avoided. Due to the biphasic characteristics of HCA, there is an obvious overlap between dosages that can lead to weight gain and the higher dosages that can lead to weight loss in those who are above their ideal body weights. There is little or no evidence that HCA ingested even in quite large amounts causes significant weight loss in individuals who are at or below their idea weights or exhibit a body mass index (BMI) at or below 20. It is to be expected that dosage will need to be matched to the current state of a given individual suffering from cachexia, catabolism or sarcopenia.

L3 ANSWER 4 OF 33 USPATFULL on STN
AN 2005:10558 USPATFULL
TI Multi-phase, multi-compartment capsular delivery apparatus and methods for using same
IN Miller, Fred H., Tampa, FL, UNITED STATES
PI US 2005008690 A1 20050113
AI US 2004-804576 A1 20040319 (10)
RLI Continuation-in-part of Ser. No. WO 2003-US10816, filed on 9 Apr 2003, PENDING
PRAI US 2002-371448P 20020410 (60)
DT Utility
FS APPLICATION
LREP FOLEY AND LARDNER, SUITE 500, 3000 K STREET NW, WASHINGTON, DC, 20007
CLMN Number of Claims: 118
ECL Exemplary Claim: 1
DRWN 13 Drawing Page(s)
LN.CNT 6126

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A multi-compartment capsule, comprising, a first receiving chamber comprising at least one ingredient having a first physical state, wherein said ingredient is selected from the group consisting of a nutraceutical, a vitamin, a dietary supplement and a mineral; and a second receiving chamber comprising at least one ingredient having a second physical state, wherein said ingredient is selected from the group consisting of a nutraceutical, a vitamin, a dietary supplement and a mineral; wherein said first physical state of said ingredient of said first receiving chamber being different from said second physical state of said ingredient of said second receiving chamber; and said ingredient of said first receiving chamber being different from said ingredient of said second receiving chamber.

L3 ANSWER 5 OF 33 USPATFULL on STN
AN 2005:3889 USPATFULL
TI Foods, beverages, condiments, spices and salad dressings with specialized supplements
IN McCleary, Edward Larry, Incline Village, NV, UNITED STATES
Forest, Carl A., Boulder, CO, UNITED STATES
McCleary, Christine, Incline Village, NV, UNITED STATES
PI US 2005002992 A1 20050106
AI US 2004-890067 A1 20040712 (10)
RLI Continuation-in-part of Ser. No. US 2003-462958, filed on 17 Jun 2003, PENDING Continuation-in-part of Ser. No. US 2003-616674, filed on 10 Jul 2003, PENDING
PRAI US 2003-520466P 20031114 (60)
US 2004-536286P 20040113 (60)
DT Utility
FS APPLICATION
LREP PATTON BOGGS, 1660 LINCOLN ST, SUITE 2050, DENVER, CO, 80264

CLMN Number of Claims: 21
ECL Exemplary Claim: 1
DRWN 1 Drawing Page(s)
LN.CNT 2674

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A food, beverage, condiment, spice or salad dressing designed to enhance the human metabolism includes a food, beverage, condiment, spice, or salad dressing base and a weight loss supplement, brain and nerve function enhancement supplement, cholesterol blocker supplement and cholesterol level improvement supplement, liver enhancement supplement, cardiac supplement, vascular supplement, anti-aging supplement, bone supplement, prostate health enhancement supplement, joint health supplement, fetus developmental (prenatal) and/or a postnatal breast milk enhancement supplement, eye health enhancement supplement, or enhanced physical performance supplement. The supplement is present in an amount in excess of the amount naturally present in the food, beverage, condiment, spice or salad dressing base.

L3 ANSWER 6 OF 33 CAPLUS COPYRIGHT 2005 ACS on STN DUPLICATE 2

AN 2004:681187 CAPLUS

DN 141:194959

TI Skin firming anti-aging cosmetic compositions

IN Gupta, Shyam K.

PA USA

SO U.S. Pat. Appl. Publ., 12 pp.

CODEN: USXXCO

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2004161435	A1	20040819	US 2003-248753	20030214
PRAI	US 2003-248753		20030214		

AB Cosmetic mask compns. suitable for face, neck, chin or body applications are disclosed. These compns. synergistically combine at least 1 skin beneficial cosmetic or pharmaceutical composition with at least one composition to promote excess fat reduction, cellulite control, or muscle toning benefits. The mask composition also contains at least one binder composition that binds with other beneficial ingredients by electrostatic, atomic, or ionic charges to synergistically enhance their topical site-specific benefits. These mask compns. are suitable for a variety of delivery system methods that include, e.g., peel-off mask, leave-in mask, moisturizing mask, and exfoliating mask. Thua, a facial mask composition contained chitosan 5.0, lactic acid 5.0, glycerin 18.0, water 65.8, **hydroxycitric acid** 5.0, niacinamide 0.5, glutathione, and preservatives 0.5%.

L3 ANSWER 7 OF 33 USPATFULL on STN

AN 2004:279824 USPATFULL

TI Cosmetic and Pharmaceutical Masks Based on Ion-Pair Delivery System

IN Gupta, Shyam K., BIODERM RESEARCH, 5221 E. Windrose Drive, Scottsdale, AZ, UNITED STATES 85254

PI US 2004219124 A1 20041104

AI US 2003-249701 A1 20030501 (10)

DT Utility

FS APPLICATION

LREP SHYAM K. GUPTA, BIODERM RESEARCH, 5221 E. WINDROSE DRIVE, SCOTTSDALE, AZ, 85254

CLMN Number of Claims: 20

ECL Exemplary Claim: 1

DRWN No Drawings

LN.CNT 802

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention discloses a novel ion-pair delivery system based mask compositions for face, hair, skin, and body applications. These compositions come off from the site of their application essentially in one piece with the appearance, for example, of a piece of sea-weed or a continuous film. These mask compositions are suitable for a variety of delivery system methods, such as peel-off mask, moisturizing mask,

exfoliating mask, prosthetic mask, soaking mask, depilatory mask, rub-off mask, two-phase mask, two-compartment mask, heat-releasing mask, and such. These mask compositions are made from the biopolymer based films that are cross-linked with divalent or trivalent metal cations. During the cross-linking process, such divalent and trivalent metal cations may also act as release agents for other face, hair, skin, and body beneficial compositions in their enhanced bioavailable forms by an ion-pair activation mechanism.

L3 ANSWER 8 OF 33 USPATFULL on STN

AN 2004:261970 USPATFULL

TI Treatment and prevention of obesity with COX-2 inhibitors alone or in combination with weight-loss agents

IN Briggs, Michael, Shrewsbury, MA, UNITED STATES

Hauser, Scott, St. Louis, MO, UNITED STATES

Ornberg, Richard, Hayward, CA, UNITED STATES

Koki, Alane, Marseille, FRANCE

PA Pharmacia Corporation, Chesterfield, MO (U.S. corporation)

PI US 2004204472 A1 20041014

AI US 2004-773019 A1 20040205 (10)

PRAI US 2003-451885P 20030304 (60)

DT Utility

FS APPLICATION

LREP Charles E. Dunlap, P.O. Box 11070, Columbia, SC, 29211-1070

CLMN Number of Claims: 15

ECL Exemplary Claim: 1

DRWN No Drawings

LN.CNT 5174

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A method for preventing or treating obesity and obesity-related complications in a subject involves a monotherapy with a Cox-2 inhibitor or a combination therapy with a Cox-2 inhibitor and a conventional weight-loss agent. Also described are therapeutic compositions comprising a Cox-2 inhibitor and a conventional weight-loss agent. Pharmaceutical compositions and kits for implementing the present method are also described.

L3 ANSWER 9 OF 33 USPATFULL on STN

AN 2004:232936 USPATFULL

TI Pharmaceutical chewing gum formulations

IN Ream, Ronald L., Plano, IL, UNITED STATES

Corriveau, Christine L., Orland Park, IL, UNITED STATES

Wokas, William J., Bolingbrook, IL, UNITED STATES

Tongue, Thomas M., JR., Joliet, IL, UNITED STATES

Greenberg, Michael J., Northbrook, IL, UNITED STATES

PI US 2004180007 A1 20040916

AI US 2003-743609 A1 20031222 (10)

RLI Continuation of Ser. No. US 2000-671552, filed on 27 Sep 2000, ABANDONED

Division of Ser. No. US 1999-286818, filed on 6 Apr 1999, PENDING

DT Utility

FS APPLICATION

LREP BELL, BOYD & LLOYD LLC, P. O. BOX 1135, CHICAGO, IL, 60690-1135

CLMN Number of Claims: 25

ECL Exemplary Claim: 1

DRWN 3 Drawing Page(s)

LN.CNT 1048

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Methods and chewing gums for delivering a medicament or agent to an individual are provided. The chewing gum includes a medicament or agent. The medicament or agent is present within the chewing gum composition (the water soluble portion and/or insoluble base portion). It has been found that by chewing the gum, the medicament or agent is released from the chewing gum. Continuing to chew the chewing gum creates a pressure within the buccal cavity forcing the agent or medicament directly into the systemic system of the individual through the oral mucosa contained in the buccal cavity. This greatly enhances the absorption of the drug into the systemic system as well as the bioavailability of the drug within the system.

L3 ANSWER 10 OF 33 USPATFULL on STN
AN 2004:196483 USPATFULL
TI Water soluble compositions derived from plant material and preparation thereof
IN Pero, Ronald W., Sandgate, VT, UNITED STATES
Worth, Lee Anthony, Upper Montclair, NJ, UNITED STATES
PI US 2004151787 A1 20040805
AI US 2003-718165 A1 20031120 (10)
PRAI US 2002-428090P 20021121 (60)
DT Utility
FS APPLICATION
LREP Patrick H. Higgins, Mathews, Collins, Shepherd & McKay, 100 Thanet Circle, Suite 306, Princeton, NJ, 08540
CLMN Number of Claims: 21
ECL Exemplary Claim: 1
DRWN 2 Drawing Page(s)
LN.CNT 788

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A process for producing a composition of water-soluble phytomedicinal compounds is provided comprising combining plant material with water, in a ratio of plant material to water within a range of about 1:5 to about 1:50, at a temperature between about 75° C. and about 100° C. for a period of time to solubilize a substantial portion of thermal aqueous extractable phytocompounds present in the plant material, to produce a first extract; and removing substantially all entities having a molecular weight greater than about 10 kd from the extract to produce a composition of water-soluble phytomedicinal compounds. Compositions of water-soluble phytomedicinal compounds are provided that exhibit improved efficacy and reduced toxicity.

L3 ANSWER 11 OF 33 USPATFULL on STN
AN 2004:126500 USPATFULL
TI Ultra-high fiber supplement and method of cancer reduction
IN Levine, Scott David, Orlando, FL, UNITED STATES
PI US 2004096479 A1 20040520
AI US 2003-704308 A1 20031110 (10)
RLI Division of Ser. No. US 2001-939385, filed on 24 Aug 2001, PENDING
DT Utility
FS APPLICATION
LREP Scott Levine MD., 7350 Sandlake Commons Blvd., Ste 2215, Orlando, FL, 32819
CLMN Number of Claims: 6
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 1683

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB An improved ultra-high fiber supplement that promotes satiety, caloric reduction, and weight loss. The supplement comprises guar, oat, psyllium, locust bean gum, pectin, green tea, multi-anthocyanadins, pyridoxine, and folic acid. It improves cardiovascular health and reduces cardiovascular **inflammation** and the risk of heart disease. The addition of antioxidants, including green tea, improves weight loss, and general and cardiovascular health. Also it reduces serum lipoprotein oxidation and risk of free-radical related diseases. Additional benefits include the lowering of plasma homocysteine by the addition of folic acid and pyridoxine. Consumption of the supplement aids in reducing absorption and assimilation of ingested toxins. A method of providing an ultra-high fiber comestible that is highly palatable and can be used to supplement nutrition and to manage and prevent diet-related diseases is disclosed. Further embodiments increase fiber and other nutrients in the diet and helps manage and prevent all diet-related diseases.

L3 ANSWER 12 OF 33 USPATFULL on STN
AN 2004:121067 USPATFULL
TI Hydroxy acids based delivery systems for skin resurfacing and anti-aging compositions

IN Gupta, Shyam K., Scottsdale, AZ, UNITED STATES
PI US 2004092482 A1 20040513
AI US 2002-290933 A1 20021107 (10)
DT Utility
FS APPLICATION
LREP SHYAM K. GUPTA, BIODERM RESEARCH, 5221 E. WINDROSE DRIVE, SCOTTSDALE,
AZ, 85254
CLMN Number of Claims: 12
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 1301

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB This invention relates to in-situ preparation of the derivatives of various hydroxy acids (HA), such as α -(Alpha) Hydroxy Acids (AHA), β -(Beta) Hydroxy Acids (BHA), and Poly-Hydroxy Acids (PHA) with certain skin beneficial organic hetero-atom bases and their application in skin resurfacing (exfoliation), and in the synergistic treatment and regulation of topical disorders of skin such as skin aging, wrinkles, acne, rosacea, age-spots, canker sores, striae distensae (stretch marks), pimples, skin redness, and dry skin conditions of cracking, flaking, and scaling. Most HA derivatives produced by the in-situ method do not cause skin irritation and skin redness effects that are commonly experienced with AHA and BHA, yet there is no loss of their skin beneficial effects. These compositions can be traditional water and oil emulsions, liposomes, suspensions, colloids, solutions, masks, muds, serums, sprays, gels, lotions, creams, cleansers, and anhydrous systems, thus offering a wide choice of formulations to meet their consumer appeal and acceptance requirements.

L3 ANSWER 13 OF 33 USPATFULL on STN
AN 2004:107273 USPATFULL
TI Niacinamide, niacin, and niacin esters based delivery systems for treating topical disorders of skin and skin aging
IN Gupta, Shyam K., Scottsdale, AZ, UNITED STATES
PI US 2004081672 A1 20040429
AI US 2002-280519 A1 20021025 (10)
DT Utility
FS APPLICATION
LREP SHYAM K. GUPTA, BIODERM RESEARCH, 5221 E. WINDROSE DRIVE, SCOTTSDALE,
AZ, 85254
CLMN Number of Claims: 29
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 1103

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to application of niacinamide, niacin, and niacin esters (nicotinic acid esters) derivatives of skin beneficial organic acids (henceforth called "derivatives") for the synergistic treatment or prevention of topical disorders of skin such as acne, rosacea, skin wrinkles, age-spots, canker sores, striae distensae (stretch marks), pimples, and skin redness. These "derivatives" are made by a very simple in-situ method. These "derivatives" provide enhanced bioavailability of both ingredients that are combined to form such derivatives. The "derivatives" of present invention can be formulated in a wide variety of delivery systems including traditional water and oil emulsions, suspensions, colloids, solutions, or anhydrous systems. Niacin and certain niacin ester derivatives prepared by the in-situ method are free of flushing effect (a warm feeling in the skin usually associated with redness and itching) normally experienced with niacin and certain niacin esters themselves.

L3 ANSWER 14 OF 33 USPATFULL on STN
AN 2004:57011 USPATFULL
TI Metabolic uncoupling therapy
IN McCleary, Edward Larry, Golden, CO, UNITED STATES
PI US 2004043013 A1 20040304
AI US 2003-462958 A1 20030617 (10)
RLI Continuation-in-part of Ser. No. US 2000-749584, filed on 28 Dec 2000,

GRANTED, Pat. No. US 6579866
DT Utility
FS APPLICATION
LREP PATTON BOGGS, PO BOX 270930, LOUISVILLE, CO, 80027
CLMN Number of Claims: 40
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 2134

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A combination of chemical agents reduces reductive stress by limiting the accumulation of high-energy electrons potentially available to the electron transport chain. A method of metabolic uncoupling therapy comprises: analyzing a specific physiologic process involving reductive stress; identifying a plurality of MUT agents that modulate metabolic pathways by influencing electron flux; and formulating a combination of MUT agents that limits the accumulation of high-energy electrons potentially available to the electron transport chain.

L3 ANSWER 15 OF 33 USPATFULL on STN DUPLICATE 3
AN 2003:37182 USPATFULL
TI Sugar-free chewy products and protein-based chewy products and methods for making the same
IN Cherukuri, Subraman Rao, Vienna, VA, UNITED STATES
Cantor, Stuart L., Eldersburg, MD, UNITED STATES
PI US 2003026826 A1 20030206
AI US 2001-24583 A1 20011221 (10)
PRAI US 2001-308566P 20010731 (60)
DT Utility
FS APPLICATION
LREP NATH & ASSOCIATES, 1030 15th STREET, 6TH FLOOR, WASHINGTON, DC, 20005
CLMN Number of Claims: 39
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 1245

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A sugar-free composition comprising a mixture of at least two polyols present in an amount from about 15 to 80% by weight, an emulsifier system present in an amount from about 1.0 to 30% by weight, an active agent in an amount from about 0.1 to 70% by weight and water in an amount from 0 to 15% by weight with optional components comprising colors, flavors and binders totalling 100%. Also, a method of preparing a sugar-free composition comprising the steps of mixing from about 15 to 80% by weight of at least two polyols with about 0 to 15% by weight water, heating the mixture to about 200-260° F. for about 5 to 10 minutes, cooling the mixture to about 175-240° F., adding to the mixture about 1.0 to 30% by weight an emulsifier system to form a further mixture, cooling the further mixture to about 100-110° F., and adding to the cooled further mixture about 0.1 to 70% by weight of an active ingredient to form the sugar-free composition. A protein-based composition comprising a mixture of at least one protein and one polyol in an amount of 20 to 99%, an emulsifier system in an amount of 0.0 to 30%, an active agent in an amount of 0.1 to 70%, and water in an amount of 0.0 to 10% are disclosed. Methods of making the protein-based compositions are also disclosed.

L3 ANSWER 16 OF 33 USPATFULL on STN
AN 2003:318329 USPATFULL
TI Pharmaceutical compositions and methods for managing connective tissue ailments
IN Murad, Howard, Marina del Ray, CA, UNITED STATES
PI US 2003224071 A1 20031204
AI US 2002-316090 A1 20021211 (10)
RLI Continuation-in-part of Ser. No. US 2002-51189, filed on 22 Jan 2002, PENDING Division of Ser. No. US 2000-641376, filed on 18 Aug 2000, GRANTED, Pat. No. US 6358539
PRAI US 1999-150034P 19990820 (60)
DT Utility
FS APPLICATION

LREP PENNIE & EDMONDS LLP, 1667 K STREET NW, SUITE 1000, WASHINGTON, DC,
20006

CLMN Number of Claims: 24

ECL Exemplary Claim: 1

DRWN No Drawings

LN.CNT 2123

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to compositions and methods for managing connective tissue disorders in a patient, a sugar compound that is converted to a glycosaminoglycan, a primary antioxidant component, at least one amino acid component, at least one transition metal component, at least one moisturizing agent, at least one fatty acid. In a preferred embodiment, the composition for topical administration to the patient's skin further included hydrogen peroxide in an amount sufficient to cleanse the skin.

L3 ANSWER 17 OF 33 USPATFULL on STN

AN 2003:126748 USPATFULL

TI Chewable product including active ingredient

IN Seielstad, Donald, Frankfort, IL, UNITED STATES

Tyrpin, Henry, Palos Park, IL, UNITED STATES

Broderick, Kevin, Berwyn, IL, UNITED STATES

Maxwell, James, Chicago, IL, UNITED STATES

Record, David, River Forest, IL, UNITED STATES

PI US 2003086960 A1 20030508

US 6602518 B2 20030805

AI US 2002-50470 A1 20020115 (10)

RLI Continuation-in-part of Ser. No. US 2001-681935, filed on 28 Jun 2001,
PENDING

DT Utility

FS APPLICATION

LREP BELL, BOYD & LLOYD LLC, P. O. BOX 1135, CHICAGO, IL, 60690-1135

CLMN Number of Claims: 35

ECL Exemplary Claim: 1

DRWN 1 Drawing Page(s)

LN.CNT 761

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Products and methods of delivering medicaments are provided. The product includes a consumable center and a compressible powder that is compressed around the center. The powder includes a medicament that may or may not be encapsulated.

L3 ANSWER 18 OF 33 USPATFULL on STN

AN 2003:70923 USPATFULL

TI Over-coated chewing gum formulations

IN Ream, Ronald L., Plano, IL, UNITED STATES

Greenberg, Michael J., Northbrook, IL, UNITED STATES

Wokas, William J., Bolingbrook, IL, UNITED STATES

Corriveau, Christine L., Orland Park, IL, UNITED STATES

PI US 2003049208 A1 20030313

US 6773716 B2 20040810

AI US 2001-992122 A1 20011113 (9)

RLI Continuation-in-part of Ser. No. US 2000-510878, filed on 23 Feb 2000,
GRANTED, Pat. No. US 6355265 Continuation-in-part of Ser. No. US
1999-286818, filed on 6 Apr 1999, PENDING

PRAI WO 1999-US29742 19991214

DT Utility

FS APPLICATION

LREP Robert M. Barrett, Bell, Boyd & Lloyd LLC, P.O. Box 1135, Chicago, IL,
60690-1135

CLMN Number of Claims: 46.

ECL Exemplary Claim: 1

DRWN 3 Drawing Page(s)

LN.CNT 1678

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Methods and products for delivering a medicament or agent to an individual are provided. The product includes a coating having a medicament or agent. The medicament or agent is present within the

coating that surrounds a center comprising a gum base. By chewing the product, the medicament or agent is released from the product. Continuing to chew the product creates a pressure within the buccal cavity forcing the agent or medicament directly into the systemic system of the individual through the oral mucosa contained in the buccal cavity. This greatly enhances the absorption of the drug into the systemic system as well as the bioavailability of the drug within the system.

L3 ANSWER 19 OF 33 USPATFULL on STN
AN 2003:29887 USPATFULL
TI Chewable product including active ingredient
IN Seielstad, Donald, Frankfort, IL, UNITED STATES
Tyrpin, Henry, Palos Park, IL, UNITED STATES
Broderick, Kevin, Berwyn, IL, UNITED STATES
Maxwell, James, Chicago, IL, UNITED STATES
Record, David, River Forest, IL, UNITED STATES
PI US 2003021830 A1 20030130
US 6613346 B2 20030902
AI US 2001-681935 A1 20010628 (9)
DT Utility
FS APPLICATION
LREP BELL, BOYD & LLOYD LLC, P. O. BOX 1135, CHICAGO, IL, 60690-1135
CLMN Number of Claims: 32
ECL Exemplary Claim: 1
DRWN 1 Drawing Page(s)
LN.CNT 806

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Products and methods of delivering medicaments are provided. The product includes a chewing gum center including a compressible powder that is compressed around the center. The powder includes a medicament that may or may not be encapsulated.

L3 ANSWER 20 OF 33 USPATFULL on STN
AN 2003:3118 USPATFULL
TI Over-coated product including tableted center and medicament
IN Ream, Ronald L., Plano, IL, UNITED STATES
Matulewicz, Leonard, Oswego, IL, UNITED STATES
Wokas, William J., Bolingbrook, IL, UNITED STATES
PI US 2003003152 A1 20030102
AI US 2002-206492 A1 20020726 (10)
RLI Division of Ser. No. US 2000-631326, filed on 3 Aug 2000, PENDING
Continuation-in-part of Ser. No. US 2000-618808, filed on 18 Jul 2000,
GRANTED, Pat. No. US 6322806 Continuation-in-part of Ser. No. US
2000-510878, filed on 23 Feb 2000, GRANTED, Pat. No. US 6355265
Continuation-in-part of Ser. No. US 1999-286818, filed on 6 Apr 1999,
PENDING
DT Utility
FS APPLICATION
LREP Bell, Boyd & Lloyd, LLC, P.O. Box 1135, Chicago, IL, 60690-1135
CLMN Number of Claims: 35
ECL Exemplary Claim: 1
DRWN 1 Drawing Page(s)
LN.CNT 1074

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Methods and products for delivering a medicament or agent to an individual are provided as well as methods for producing the product. The product includes a coating having a medicament or agent. The medicament or agent is present within the coating that surrounds a tableted center. The tableted center is defined by compressible excipients. By chewing the product, the medicament or agent is released from the product within the buccal cavity.

L3 ANSWER 21 OF 33 USPATFULL on STN
AN 2002:330260 USPATFULL
TI Bioavailable composition of natural and synthetic hca
IN Majeed, Muhammed, Piscataway, NJ, UNITED STATES
Hadmaev, Vladimir, Piscataway, NJ, UNITED STATES

PI US 2002187943 A1 20021212
AI US 2002-926746 A1 20020606 (9)
WO 2001-US41748 20010817
DT Utility
FS APPLICATION
LREP ARENT FOX KINTNER PLOTKIN & KAHN, 1050 CONNECTICUT AVENUE, N.W., SUITE
400, WASHINGTON, DC, 20036
CLMN Number of Claims: 28
ECL Exemplary Claim: 1
DRWN 19 Drawing Page(s)
LN.CNT 670

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention relates to a composition comprising **hydroxycitric acid** (HCA) in combination with either one or both of garcinol and anthocyanin, and its use as a weight-loss therapy in animal subjects, preferably humans. The therapeutic effects for the composition observed in murine and human studies include a reduction in total body weight and body mass index, a reduction in body fat, an increase in lean body mass and content of body water, and a reduction in perceived appetite level. Another composition for use in weight-loss therapy is also described relating to forskolin in combination with either one or both of garcinol and anthocyanin. The anti-oxidant properties of garcinol are described as being enhanced in the presence of HCA and anthocyanin, and the combination of HCA, garcinol and anthocyanin is also shown to exert greater citrate lyase inhibiting properties than either compound alone. Methods of obtaining HCA, garcinol or anthocyanin, or a composition containing all three compounds, are described.

L3 ANSWER 22 OF 33 USPATFULL on STN
AN 2002:287098 USPATFULL
TI Over-coated chewing gum formulations
IN Ream, Ronald L., Plano, IL, UNITED STATES
Greenberg, Michael J., Northbrook, IL, UNITED STATES
Wokas, William J., Bolingbrook, IL, UNITED STATES
Corriveau, Christine L., Orland Park, IL, UNITED STATES
PI US 2002159956 A1 20021031
AI US 2001-990628 A1 20011113 (9)
RLI Continuation-in-part of Ser. No. US 2000-510878, filed on 23 Feb 2000,
GRANTED, Pat. No. US 6355265 Continuation-in-part of Ser. No. US
1999-286818, filed on 6 Apr 1999, PENDING
PRAI WO 1999-US29742 19991214
DT Utility
FS APPLICATION
LREP BELL, BOYD & LLOYD LLC, P. O. BOX 1135, CHICAGO, IL, 60690-1135
CLMN Number of Claims: 34
ECL Exemplary Claim: 1
DRWN 4 Drawing Page(s)
LN.CNT 1596

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Methods and products for delivering a medicament or agent to an individual are provided. The product includes a coating having a medicament or agent. The medicament or agent is present within the coating that surrounds a gum center (the water soluble portion and a water insoluble base portion). By chewing the gum, the medicament or agent is released from the product. Continuing to chew the chewing gum creates a pressure within the buccal cavity forcing the agent or medicament directly into the systemic system of the individual through the oral mucosa contained in the buccal cavity. This greatly enhances the absorption of the drug into the systemic system as well as the bioavailability of the drug within the system.

L3 ANSWER 23 OF 33 USPATFULL on STN
AN 2002:205893 USPATFULL
TI Over-coated product including consumable center and medicament
IN Ream, Ronald L., Plano, IL, UNITED STATES
Matulewicz, Leonard, Oswego, IL, UNITED STATES
Wokas, William J., Bolingbrook, IL, UNITED STATES

PI US 2002110581 A1 20020815
AI US 2002-44113 A1 20020109 (10)
RLI Continuation-in-part of Ser. No. US 2000-631326, filed on 3 Aug 2000,
PENDING Continuation-in-part of Ser. No. US 2000-510878, filed on 23 Feb
2000, PATENTED Continuation-in-part of Ser. No. US 1999-286818, filed on
6 Apr 1999, PENDING
DT Utility
FS APPLICATION
LREP BELL, BOYD & LLOYD LLC, P. O. BOX 1135, CHICAGO, IL, 60690-1135
CLMN Number of Claims: 35
ECL Exemplary Claim: 1
DRWN 1 Drawing Page(s)
LN.CNT 1160

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Methods and products for delivering a medicament or agent to an
individual are provided as well as methods for producing the product.
The product includes a coating having a medicament or agent. The
medicament or agent is present within the coating that surrounds a
consumable center. By chewing the product, the medicament or agent is
released from the product within the buccal cavity.

L3 ANSWER 24 OF 33 USPATFULL on STN
AN 2002:72424 USPATFULL
TI Over-coated chewing gum formulations
IN Ream, Ronald L., Plano, IL, UNITED STATES
Greenberg, Michael J., Northbrook, IL, UNITED STATES
Wokas, William J., Bolingbrook, IL, UNITED STATES
Corriveau, Christine L., Orland Park, IL, UNITED STATES

PI US 2002039560 A1 20020404
US 6465003 B2 20021015
AI US 2001-924914 A1 20010808 (9)
RLI Division of Ser. No. US 2001-759561, filed on 11 Jan 2001, PENDING
Continuation-in-part of Ser. No. US 2000-510878, filed on 23 Feb 2000,
PENDING Division of Ser. No. US 1999-286818, filed on 6 Apr 1999,
PENDING

DT Utility
FS APPLICATION
LREP Hill & Simpson, A Professional Corporation, 85th Floor Sears Tower,
Chicago, IL, 60606
CLMN Number of Claims: 54
ECL Exemplary Claim: 1
DRWN 3 Drawing Page(s)
LN.CNT 1677

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Methods and products for delivering a medicament or agent to an
individual are provided. The product includes a coating having a
medicament or agent. The medicament or agent is present within the
coating that surrounds a gum center (the water soluble portion and a
water insoluble base portion). By chewing the gum, the medicament or
agent is released from the product. Continuing to chew the chewing gum
creates a pressure within the buccal cavity forcing the agent or
medicament directly into the systemic system of the individual through
the oral mucosa contained in the buccal cavity. This greatly enhances
the absorption of the drug into the systemic system as well as the
bioavailability of the drug within the system.

L3 ANSWER 25 OF 33 USPATFULL on STN
AN 2002:304017 USPATFULL
TI (-)-hydroxycitric acid for wound healing and
immunomodulation
IN Clouatre, Dallas L, 555 Bryant St., #357, Palo Alto, CA, United States
94301-1704
Dunn, James M, 3236 Hinsdale Pl., Littleton, CO, United States 80112

PI US 6482858 B1 20021119
AI US 2001-886572 20010620 (9)
DT Utility
FS GRANTED
EXNAM Primary Examiner: Spivack, Phyllis G.

CLMN Number of Claims: 12
ECL Exemplary Claim: 1
DRWN 0 Drawing Figure(s); 0 Drawing Page(s)
LN.CNT 876

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB HCA Supplementation improves wound healing and immunomodulation/immunoregulation, including improving depressed immune function and also reducing excessive immune activity such as is found in elevated humoral immunity linked to allergies and autoimmune diseases. The benefits of HCA are especially pronounced with the use of the preferred salt of the acid, potassium hydroxycitrate, and may be further potentiated by the use of a controlled-release form of the compound.

L3 ANSWER 26 OF 33 USPATFULL on STN
AN 2002:188140 USPATFULL
TI Over-coated product including tableted center and medicament
IN Ream, Ronald L., Plano, IL, United States
Matulewicz, Leonard, Oswego, IL, United States
Wokas, William J., Bolingbrook, IL, United States
PA Wm. Wrigley Jr. Company, Chicago, IL, United States (U.S. corporation)
PI US 6426090 B1 20020730
AI US 2001-955870 20010919 (9)
RLI Division of Ser. No. US 2000-631326, filed on 3 Aug 2000
Continuation-in-part of Ser. No. US 2000-618808, filed on 18 Jul 2000
Continuation-in-part of Ser. No. US 2000-510878, filed on 23 Feb 2000
Continuation-in-part of Ser. No. WO 1999-US29742, filed on 14 Dec 1999
Continuation-in-part of Ser. No. US 1999-286818, filed on 6 Apr 1999

DT Utility
FS GRANTED

EXNAM Primary Examiner: Page, Thurman K.; Assistant Examiner: Howard, S.

LREP Bell, Boyd & Lloyd LLC

CLMN Number of Claims: 15

ECL Exemplary Claim: 1

DRWN 1 Drawing Figure(s); 1 Drawing Page(s)

LN.CNT 952

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Methods and products for delivering a medicament or agent to an individual are provided as well as methods for producing the product. The product includes a coating having a medicament or agent. The medicament or agent is present within the coating that surrounds a tableted center. The tableted center is defined by compressible excipients. By chewing the product, the medicament or agent is released from the product within the buccal cavity.

L3 ANSWER 27 OF 33 USPATFULL on STN
AN 2002:50631 USPATFULL
TI Over-coated chewing gum formulations
IN Ream, Ronald L., Plano, IL, United States
Greenberg, Michael J., Northbrook, IL, United States
Wokas, William J., Bolingbrook, IL, United States
Corriveau, Christine L., Orland Park, IL, United States
PA Wm. Wrigley Jr. Company, Chicago, IL, United States (U.S. corporation)
PI US 6355265 B1 20020312
AI US 2000-510878 20000223 (9)
RLI Continuation-in-part of Ser. No. US 1999-286818, filed on 6 Apr 1999
Continuation-in-part of Ser. No. WO 1999-US29742, filed on 14 Dec 1999

DT Utility
FS GRANTED

EXNAM Primary Examiner: Page, Thurman K.; Assistant Examiner: Howard, S.

LREP Bell, Boyd & Lloyd LLC

CLMN Number of Claims: 18

ECL Exemplary Claim: 1

DRWN 4 Drawing Figure(s); 3 Drawing Page(s)

LN.CNT 1508

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Methods and products for delivering a medicament or agent to an individual are provided. The product includes a coating having a medicament or agent. The medicament or agent is present within the

coating that surrounds a gum center (the water soluble portion and a water insoluble base portion). By chewing the gum, the medicament or agent is released from the product. Continuing to chew the chewing gum creates a pressure within the buccal cavity forcing the agent or medicament directly into the systemic system of the individual through the oral mucosa contained in the buccal cavity. This greatly enhances the absorption of the drug into the systemic system as well as the bioavailability of the drug within the system.

L3 ANSWER 28 OF 33 USPATFULL on STN
AN 2001:165432 USPATFULL
TI Over-coated chewing gum formulations
IN Ream, Ronald L., Plano, IL, United States
Greenberg, Michael J., Northbrook, IL, United States
Wokas, William J., Bolingbrook, IL, United States
Corriveau, Christine L., Orland Park, IL, United States
PI US 2001024642 A1 20010927
US 6558692 B2 20030506
AI US 2001-759561 A1 20010111 (9)
RLI Division of Ser. No. US 2000-510878, filed on 23 Feb 2000, PENDING
Continuation-in-part of Ser. No. US 1999-286818, filed on 6 Apr 1999,
PENDING Continuation-in-part of Ser. No. WO 1999-US29742, filed on 14
Dec 1999, UNKNOWN
DT Utility
FS APPLICATION
LREP Bell, Boyd & Lloyd, LLC, P.O. Box 1135, Chicago, IL, 60690-1135
CLMN Number of Claims: 54
ECL Exemplary Claim: 1
DRWN 3 Drawing Page(s)
LN.CNT 1670

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Methods and products for delivering a medicament or agent to an individual are provided. The product includes a coating having a medicament or agent. The medicament or agent is present within the coating that surrounds a gum center (the water soluble portion and a water insoluble base portion). By chewing the gum, the medicament or agent is released from the product. Continuing to chew the chewing gum creates a pressure within the buccal cavity forcing the agent or medicament directly into the systemic system of the individual through the oral mucosa contained in the buccal cavity. This greatly enhances the absorption of the drug into the systemic system as well as the bioavailability of the drug within the system.

L3 ANSWER 29 OF 33 USPATFULL on STN
AN 2001:90853 USPATFULL
TI Over-coated chewing gum formulations including tableted center
IN Ream, Ronald L., Plano, IL, United States
Corriveau, Christine L., Orland Park, IL, United States
Graff, Gwendolyn, DeKalb, IL, United States
Matulewicz, Leonard, Oswego, IL, United States
PI US 2001002998 A1 20010607
US 6290985 B2 20010918
AI US 2001-759838 A1 20010111 (9)
RLI Division of Ser. No. US 2000-618808, filed on 18 Jul 2000, UNKNOWN
DT Utility
FS APPLICATION
LREP Robert M. Barrett, Esq., BELL BOYD & LLOYD LLC, P.O. Box 1135, Chicago, IL, 60690-1135
CLMN Number of Claims: 47
ECL Exemplary Claim: 1
DRWN 4 Drawing Page(s)
LN.CNT 1685

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Methods and products for delivering a medicament or agent to an individual are provided as well as methods for producing the product. The product includes a coating having a medicament or agent. The medicament or agent is present within the coating that surrounds a tableted gum center (the water soluble portion and a water insoluble

base portion). By chewing the gum, the medicament or agent is released from the product. Continuing to chew the chewing gum creates a pressure within the buccal cavity forcing the agent or medicament directly into the systemic system of the individual through the oral mucosa contained in the buccal cavity. This greatly enhances the absorption of the drug into the systemic system as well as the bioavailability of the drug within the system.

L3 ANSWER 30 OF 33 USPATFULL on STN
AN 2001:214675 USPATFULL
TI Over-coated chewing gum formulations including tableted center
IN Ream, Ronald L., Plano, IL, United States
Corriveau, Christine L., Orland Park, IL, United States
Graff, Gwendolyn, DeKalb, IL, United States
Matulewicz, Leonard, Oswego, IL, United States
PA Wm. Wrigley Jr. Company, Chicago, IL, United States (U.S. corporation)
PI US 6322806 B1 20011127
AI US 2000-618808 20000718 (9)
RLI Continuation-in-part of Ser. No. US 2000-510878, filed on 23 Feb 2000
Continuation-in-part of Ser. No. WO 1999-US29742, filed on 14 Dec 1999
Continuation-in-part of Ser. No. US 1999-286818, filed on 6 Apr 1999
DT Utility
FS GRANTED
EXNAM Primary Examiner: Page, Thurman K.; Assistant Examiner: Howard, S.
LREP Bell, Boyd & Lloyd LLC
CLMN Number of Claims: 36
ECL Exemplary Claim: 1
DRWN 4 Drawing Figure(s); 3 Drawing Page(s)
LN.CNT 1715
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Methods and products for delivering a medicament or agent to an individual are provided as well as methods for producing the product. The product includes a coating having a medicament or agent. The medicament or agent is present within the coating that surrounds a tableted gum center (the water soluble portion and a water insoluble base portion). By chewing the gum, the medicament or agent is released from the product. Continuing to chew the chewing gum creates a pressure within the buccal cavity forcing the agent or medicament directly into the systemic system of the individual through the oral mucosa contained in the buccal cavity. This greatly enhances the absorption of the drug into the systemic system as well as the bioavailability of the drug within the system.

L3 ANSWER 31 OF 33 USPATFULL on STN
AN 1999:132273 USPATFULL
TI Use of piperine as a bioavailability enhancer
IN Majeed, Muhammed, Piscataway, NJ, United States
Badmaev, Vladimir, Piscataway, NJ, United States
Rajendran, R., Bangalore, India
PA Sabinsa Corporation, Piscataway, NJ, United States (U.S. corporation)
PI US 5972382 19991026
AI US 1998-5594 19980112 (9)
RLI Division of Ser. No. US 1995-550496, filed on 30 Oct 1995, now patented, Pat. No. US 5744161 which is a continuation-in-part of Ser. No. US 1995-393738, filed on 24 Feb 1995, now patented, Pat. No. US 5536506
DT Utility
FS Granted
EXNAM Primary Examiner: Azpuru, Carlos A.
LREP Nikaido Marmelstein Murray & Oram, LLP
CLMN Number of Claims: 60
ECL Exemplary Claim: 1
DRWN 3 Drawing Figure(s); 3 Drawing Page(s)
LN.CNT 1159
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Compositions and methods for the improvement of gastrointestinal absorption and systemic utilization of nutrients and nutritional supplements, wherein the compositions comprise a minimum of 98% of pure alkaloid piperine. The method comprises oral, topical, or parenteral

administration of the compositions of the invention. A new process for the extraction and purification of piperine is also disclosed.

L3 ANSWER 32 OF 33 USPATFULL on STN
AN 1998:44905 USPATFULL
TI Use of piperine as a bioavailability enhancer
IN Majeed, Muhammed, Piscataway, NJ, United States
Badmaev, Vladimir, Piscataway, NJ, United States
Rajendran, Ramaswamy, Jayanagar Eastend, India
PA Sabinsa Corporation, Piscataway, NJ, United States (U.S. corporation)
PI US 5744161 19980428
AI US 1995-550496 19951030 (8)
RLI Continuation-in-part of Ser. No. US 1995-393738, filed on 24 Feb 1995,
now patented, Pat. No. US 5536506
DT Utility
FS Granted
EXNAM Primary Examiner: Azpuru, Carlos A.
LREP Nikaido, Marmelstein, Murray & Oram LLP
CLMN Number of Claims: 35
ECL Exemplary Claim: 1
DRWN 3 Drawing Figure(s); 3 Drawing Page(s)
LN.CNT 991
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Compositions and methods for the improvement of gastrointestinal
absorption and systemic utilization of nutrients and nutritional
supplements, wherein the compositions comprise a minimum of 98% of pure
alkaloid piperine. The method comprises oral, topical, or parenteral
administration of the compositions of the invention. A new process for
the extraction and purification of piperine is also disclosed.

L3 ANSWER 33 OF 33 MEDLINE on STN
AN 89285933 MEDLINE
DN PubMed ID: 2500054
TI Aging, diet, and the acute-phase response to inflammation.
AU Hellerstein M K
CS Department of Nutritional Science, University of California, Berkeley
94720.
SO Annals of the New York Academy of Sciences, (1989) 561 178-95.
Journal code: 7506858. ISSN: 0077-8923.
CY United States
DT Journal; Article; (JOURNAL ARTICLE)
LA English
FS Priority Journals
EM 198907
ED Entered STN: 19900309
Last Updated on STN: 19970203
Entered Medline: 19890727